Northern Design Centre
Baltic Business Quarter
Gateshead NE8 3DF
United Kingdom
44 1915 118 500
https://www.shieldtherapeutics.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 27
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Gregory P. Madison | CEO & Executive Director | 678k | N/A | 1967 |
Dr. Christian Schweiger M.D., Ph.D. | Co-Founder & Non Executive Director | 45k | N/A | 1966 |
Mr. Santosh Shanbhag | Chief Financial Officer | N/A | N/A | 1978 |
Ms. Lucy Kate Huntington-Bailey | General Counsel & Company Secretary | N/A | N/A | N/A |
Ms. Suzanne Wood | Group HR Director | N/A | N/A | N/A |
Ms. Carol Akinola | Head of Pharmacovigilance & Medical Information | N/A | N/A | N/A |
Mr. Andrew Hurley | Chief Commercial Officer | N/A | N/A | 1969 |
Kate Armanetti | Senior Director of People & Culture | N/A | N/A | N/A |
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.